Biomedical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-7360-538437

Research Article - Biomedical Research (2018) Volume 29, Issue 3

Comprehensive analysis clinical effectiveness of Tirofiban for patients with non-ST-elevation acute coronary syndrome

Background: To systematically assess the effectiveness and safety of tirofiban in patients with non-STelevation acute coronary syndromes (NSTE-ACS).

Methods: We search the online databases in both English and Chinese from inception to 2017 to collect randomized controlled trials about tirofiban for NSTE-ACS patients in early medicine conservative treatment. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality of included studies.

Results: A total of 10 randomized controlled trials were enrolled involving 6405 patients. The results of meta-analysis showed that: (1) The incidences of cardiovascular events of composite endpoints in the trial group were lower than that in the control group (during One week: relative risk (RR)=0.55, 95% confidence interval (95%CI: 0.40, 0.74, P<0.001) and the incidences of cardiovascular events of composite endpoints in the trial group were lower than that in the control group (during 30 days: RR=0.45, 95%CI0.40, 0.75, P<0.001). (2) The incidence of bleeding in the trial group was higher than that in the control group (RR=1.31, 95%CI: 1.00-1.72).

Conclusions: Compared with routine treatment alone, tirofiban has better therapeutic effects in early conservative treatment for patients with non-ST-elevation acute coronary syndromes, but the incidence of bleeding is relatively high.

Author(s): Jianfei Zheng, Xudong Xiang, Huixia Li, Bing Xiao, Ting Yuan, Xun Gong, Shuo Yao

Abstract Full Text PDF

Get the App